Literature DB >> 33637604

Longitudinal Immune Profiling Reveals Unique Myeloid and T-cell Phenotypes Associated with Spontaneous Immunoediting in a Prostate Tumor Model.

Casey R Ager1, Aleksandar Z Obradovic1,2, Juan M Arriaga3, Matthew G Chaimowitz1, Andrea Califano2,4,5,6,7,8, Cory Abate-Shen2,3,4,9,10, Charles G Drake11,9,12.   

Abstract

The theory of cancer immunoediting, which describes the dynamic interactions between tumors and host immune cells that shape the character of each compartment, is foundational for understanding cancer immunotherapy. Few models exist that facilitate in-depth study of each of the three canonical phases of immunoediting: elimination, equilibrium, and escape. Here, we utilized NPK-C1, a transplantable prostate tumor model that we found recapitulated the three phases of immunoediting spontaneously in immunocompetent animals. Given that a significant portion of NPK-C1 tumors reliably progressed to the escape phase, we were able to delineate cell types and mechanisms differentially prevalent in equilibrium versus escape phases. Using high-dimensional flow cytometry, we found that activated CD4+ effector T cells were enriched in regressing tumors, highlighting a role for CD4+ T cells in antitumor immunity. CD8+ T cells were also important for NPK-C1 control, specifically, central memory-like cytotoxic CD8+ T cells. Regulatory T cells (Treg), as a whole, were counterintuitively enriched in regressing tumors; however, high-dimensional analysis revealed their significant phenotypic diversity, with a number of Treg subpopulations enriched in progressing tumors. In the myeloid compartment, we found that iNOS+ dendritic cell (DC)-like cells are enriched in regressing tumors, whereas CD103+ DCs were associated with late-stage tumor progression. In total, these analyses of the NPK-C1 model provide novel insights into the roles of lymphoid and myeloid populations throughout the cancer immunoediting process and highlight a role for multidimensional, flow-based analyses to more deeply understand immune cell dynamics in the tumor microenvironment. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33637604      PMCID: PMC8102339          DOI: 10.1158/2326-6066.CIR-20-0637

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   12.020


  33 in total

1.  Lack of immunoediting in murine pancreatic cancer reversed with neoantigen.

Authors:  Rebecca A Evans; Mark S Diamond; Andrew J Rech; Timothy Chao; Max W Richardson; Jeffrey H Lin; David L Bajor; Katelyn T Byrne; Ben Z Stanger; James L Riley; Nune Markosyan; Rafael Winograd; Robert H Vonderheide
Journal:  JCI Insight       Date:  2016-09-08

Review 2.  CD4+ T cell help in cancer immunology and immunotherapy.

Authors:  Jannie Borst; Tomasz Ahrends; Nikolina Bąbała; Cornelis J M Melief; Wolfgang Kastenmüller
Journal:  Nat Rev Immunol       Date:  2018-10       Impact factor: 53.106

3.  ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.

Authors:  Alvaro Aytes; Antonina Mitrofanova; Carolyn Waugh Kinkade; Celine Lefebvre; Ming Lei; Vanessa Phelan; H Carl LeKaye; Jason A Koutcher; Robert D Cardiff; Andrea Califano; Michael M Shen; Cory Abate-Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-05       Impact factor: 11.205

Review 4.  T Cell Dysfunction in Cancer.

Authors:  Daniela S Thommen; Ton N Schumacher
Journal:  Cancer Cell       Date:  2018-04-09       Impact factor: 31.743

Review 5.  New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.

Authors:  Deepak Mittal; Matthew M Gubin; Robert D Schreiber; Mark J Smyth
Journal:  Curr Opin Immunol       Date:  2014-02-14       Impact factor: 7.486

6.  Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.

Authors:  Priyamvada Jayaprakash; Midan Ai; Arthur Liu; Pratha Budhani; Todd Bartkowiak; Jie Sheng; Casey Ager; Courtney Nicholas; Ashvin R Jaiswal; Yanqiu Sun; Krishna Shah; Sadhana Balasubramanyam; Nan Li; Guocan Wang; Jing Ning; Anna Zal; Tomasz Zal; Michael A Curran
Journal:  J Clin Invest       Date:  2018-10-15       Impact factor: 14.808

7.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells.

Authors:  Mercedes B Fuertes; Aalok K Kacha; Justin Kline; Seng-Ryong Woo; David M Kranz; Kenneth M Murphy; Thomas F Gajewski
Journal:  J Exp Med       Date:  2011-09-19       Impact factor: 14.307

Review 8.  Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis.

Authors:  Bin Shang; Yao Liu; Shu-juan Jiang; Yi Liu
Journal:  Sci Rep       Date:  2015-10-14       Impact factor: 4.379

9.  MHC-II neoantigens shape tumour immunity and response to immunotherapy.

Authors:  Elise Alspach; Danielle M Lussier; Alexander P Miceli; Ilya Kizhvatov; Michel DuPage; Adrienne M Luoma; Wei Meng; Cheryl F Lichti; Ekaterina Esaulova; Anthony N Vomund; Daniele Runci; Jeffrey P Ward; Matthew M Gubin; Ruan F V Medrano; Cora D Arthur; J Michael White; Kathleen C F Sheehan; Alex Chen; Kai W Wucherpfennig; Tyler Jacks; Emil R Unanue; Maxim N Artyomov; Robert D Schreiber
Journal:  Nature       Date:  2019-10-23       Impact factor: 49.962

10.  Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.

Authors:  Kai Hildner; Brian T Edelson; Whitney E Purtha; Mark Diamond; Hirokazu Matsushita; Masako Kohyama; Boris Calderon; Barbara U Schraml; Emil R Unanue; Michael S Diamond; Robert D Schreiber; Theresa L Murphy; Kenneth M Murphy
Journal:  Science       Date:  2008-11-14       Impact factor: 47.728

View more
  2 in total

1.  TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism.

Authors:  Kaikai Zhao; Liyang Jiang; Youjiao Si; Shujie Zhou; Zhaoqin Huang; Xiangjiao Meng
Journal:  Cancer Immunol Immunother       Date:  2022-07-06       Impact factor: 6.968

Review 2.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.